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Abstract 
Background: Previous studies of heart failure patients have demonstrated an association 
between cardiovascular medication adherence and hospitalizations or a composite end point of 
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hospitalization and death.  Few studies have assessed the impact of treatment adherence 
within large general medical populations that distinguish the health outcomes of emergency 
department visits, hospitalization, and death.  
Objective: To determine the association of incremental cardiovascular medication adherence 
on emergency department visits, hospitalization, and death in adult heart failure patients in 
Indiana.  
Design: Retrospective cohort study conducted using electronic health record data from the 
statewide Indiana Network for Patient Care (INPC) between 2004 and 2009.  
Methods: Patients were at least 18 years of age with a diagnosis of heart failure and prescribed 
at least one cardiovascular medication for heart failure. Adherence was measured as the 
proportion of days covered (PDC) using pharmacy transaction data. Clinical end points included 
emergency department visits, hospital admissions, length of hospital stay, and mortality. 
Generalized linear models were used to determine the effect of a 10% increase in PDC on 
clinical end points adjusting for age, sex, race, Charlson comorbidity index, and medications.   
Results: Electronic health records were available for 55,312 patients (mean age ± standard 
deviation [SD] 68 ± 16 years; 54% women; 65% white). Mean PDC for all heart failure 
medications was 63% ± 23%. For every 10% increase in PDC, emergency department visits 
decreased 11% (rate ratio [RR] 0.89; 95% confidence interval [CI] 0.89-0.89), hospital 
admissions decreased 6% (RR 0.94; 95% CI 0.94-0.94), total length of hospital stay decreased 
1% (RR 0.99; 95% CI 0.99-1.00), and all-cause mortality decreased 9% (odds ratio 0.91; 95% CI 
0.90-0.92).  
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Conclusion: Incremental medication adherence was associated with reductions in emergency 
department visits, hospital admissions, length of hospital stay, and all-cause mortality.  
 
Chronic heart failure affects more than 6.5 million Americans and its prevalence may increase to more 
than 8 million Americans by 2030.1 It is a global disease, contributing to one in eight deaths and is 
increasing in areas where the risk factors for heart failure are common, such as in aging, ischemic heart 
disease, and hypertension.1 Patients diagnosed with heart failure are often prescribed multiple 
medications for which they have low treatment adherence resulting in poor health outcomes and costly 
care.2  Indeed, more than 500,000 heart failure-related hospitalizations occur each year with direct 
health care costs projected to reach $69.7 billion in the United States by 2030.1 It is well documented 
that adherence to medication is a vital part of the self-care management of heart failure.3-7 
Notwithstanding, many heart failure patients fail to take their medications as prescribed at the risk of 
adverse health outcomes,8 including death.9 Interventions aimed at improving adherence to heart failure 
medications, however, reduce hospital readmissions and mortality.10   
 Many previous observational studies analyzing adherence had too few patients to examine an 
incremental effect of adherence on death or they focused mainly on patient characteristics rather than 
on health outcomes.3-7,11 We identified multiple studies associating patient adherence to frequency of 
and time to clinical events such as cardiovascular7 or heart failure-related hospitalizations or a 
composite end point of these end points coupled with death.3,4,6,11 Studies of composite end points 
including death and those end points looking exclusively at hospitalizations had statistically significant 
results. However, these studies did not find a significant effect on death as an independent end point 
yet there were non-significant trends of an increased death rate with poor adherence.  Our previous 
randomized trial of a pharmacist intervention aimed at improving adherence in heart failure patients 
had a favorable impact on emergency department visits and hospitalizations but had too few 
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participants to assess the effects of adherence on mortality.12 We wanted to know whether the impact 
of improvements in treatment adherence translated to the broad population of patients in our state of 
Indiana so we conducted an observational study to determine the association between treatment 
adherence on health outcomes including urgent care, hospitalization, and death using data from a 
statewide health information exchange. 
 
Methods 
Patients 
We extracted data from a health information exchange containing 55,312 patients with heart failure 
between January 1, 2004 and December 31, 2009.  We included patients who were at least 18 years old, 
had an ICD9 code for heart failure (ICD9 codes 428.*), and were prescribed at least one outpatient 
cardiovascular medication with at least two prescription refills to treat heart failure during the study 
period.  Heart failure medications considered included angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers (ARBs), beta-blockers, calcium-channel blockers, digoxin, diuretics, and 
the aldosterone antagonists, spironolactone or eplerenone. Prescription records were obtained from 
Surescripts®, a pharmacy transaction processing network that connects greater than 90% of retail 
pharmacies in Indiana, during the study period.13  
 
Data Source 
 Patients’ digital health records were extracted from the Indiana Network for Patient Care (INPC). Most 
of the data extracted were coded elements. However, we attempted to obtain selected data such as 
functional health status using text mining of clinician notes within the health records. This health 
information exchange captures and stores digital health data across the state of Indiana including 
laboratory results, inpatient and outpatient encounter data (including urgent and emergent care), coded 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
diagnoses and procedures, and digital prescription records among other information from the major 
health care systems in Indiana.14 The presence or absence of relevant comorbidities were derived from 
extracted ICD9 codes and physicians’ problem lists for the patient and were used to calculate the 
Charlson Comorbidity Index for each patient.15 Generally, this interconnected health exchange is 
invaluable in reducing missing data from patients who receive their care from more than one health 
care system. However, we could only report on results that were accessible from these digital health 
records. For example, if a patient did not have a particular laboratory test, there would be no accessible 
result for that test to extract. Most of the data for the present study derived from Marion County and 
surrounding counties (greater Indianapolis). Death data are available from the Indiana State Department 
of Health and, at the time of the data extraction, were most accurate from 2004 to 2009. All data were 
de-identified prior to analysis. The Indiana University Purdue University of Indianapolis (IUPUI) 
Institutional Review Board granted approval for this study.  
 
Study Design 
This retrospective cohort study examined pharmacy transaction data for patients with heart failure to 
determine the percentage of days covered (PDC) as an estimate of their medication adherence.  We 
used the method described by Nau16 with a time off-set as recommended by Bijlsma and colleagues. 17 
As proposed by Nau, we defined the PDC measurement frame as the date of the first/index prescription 
and the last date of the prescription plus the days covered with the last prescription or the last 
encounter in any one of the health systems of the INPC, or death. We then calculated the number of 
days by drugs in a specific class or overall drug classes.  We then divided the number of days of drug 
coverage by the PDC measurement frame. We calculated the incremental adherence (in 10% 
increments) and examined the association of 10% increments on hospital admissions, number of 
emergency department visits, length of hospital stay, and all-cause mortality. 
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Statistical Methods 
 Descriptive statistics including means and standard deviations for continuous data and counts and 
percentages for categorical data were calculated on patient characteristics and PDC usage.  T-tests and 
one-way analysis of variance models were used to compare the PDC usage across patient characteristics.  
A mixed effects model with a random subject effect was used to compare PDCs from various drug 
classes. A logistic regression model was used to determine the effect of a 10% PDC increase on 
mortality.  Similarly, Poisson regression models were used on the remaining aforementioned outcomes.  
Models were adjusted for patient age, self-identified race, sex, number of cardiovascular medications, 
and Charlson comorbidity index. We specified a p value of less than 0.05 as statistically significant. 
 
Results 
Patient Characteristics 
Participants included in the study were mostly older adults with an average (standard deviation [SD]) 
age of 68 ± 16 years old, women (54%), and white (65%) (Table 1). Patients were followed for a mean of 
4.7 ± 2.2 years of observation and prescription history (the range was 0-41.4 years, median 4.7 years, 
and the interquartile range [IQR] was 2.8-6.6 years). The range of refills was 2 to 2582 with a mean of 
151.4 ± 155.8. We found limited data within the digital clinical notes on patient functional health status 
as measured by clinicians using the New York Heart Association (NYHA) classification (only 2.1% of 
patients), which were Class I (22%), II (37%), III (31%), or IV (10%). Patients had a mean of 3.8 ± 8.9 
emergency department visits, 7.8 ± 14.1 hospitalizations, and a mean cumulative number of hospital 
days of 36.4 ± 108.4 days (approximately 4.7 days per visit).  There were 8515 (15%) deaths in the study. 
 The mean PDC ± SD for all medications was 63 ± 23% and varied by self-identified race/ethnicity. 
The PDC was highest for non-Hispanic Whites (65%), followed by Other race (60%), non-Hispanic African 
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Americans (57%), and Hispanics (50%) (p<0.0001). The mean PDC ± SD was similar for men and women 
at 62.8 ± 22.8% and 62.7 ± 22.5%, respectively (p=0.4916). Additionally, the PDC varied by type of 
cardiovascular medication taken as shown in Table 2.  In particular, diuretics had lower PDCs than the 
ACE inhibitors, ARBs, and beta-blockers (p<0.0001, controlling for multiple comparisons). 
The multivariable model of the predictors of mortality including incremental changes in PDC is shown in 
Table 3.  Notably, each 10% increase in overall PDC reduced the risk of death by 9% (odds ratio [OR], 
0.91; 95% confidence interval [CI], 0.90-0.92).  Compared to males, females had a slightly increased risk 
of death (OR, 1.06; 95% CI, 1.00-1.11). While the difference in mortality between black and white 
patients was not statistically significant, patients within the Other category of race/ethnicity who self-
identified as Hispanic, Asian, Native American, Multiracial, or American Indian/Alaskan had a decreased 
risk of death compared with whites (OR, 0.45; 95% CI, 0.34-0.60). Age and comorbid conditions 
significantly increased the risk of death, but the numbers of cardiovascular drugs reduced this risk (OR, 
0.84; 95% CI, 0.83-0.86). 
 As shown in Table 4, we found that improvements in adherence by 10% increments significantly 
reduced emergency department visits by 11% (rate ratio [RR], 0.89; 95% CI, 0.89-0.89), hospital 
admissions by 6% (RR, 0.94; 95% CI, 0.94-0.94), and total length of stay by 2% (RR, 0.99; 95% CI, 0.99-
1.00). All utilization outcomes were statistically significant (p<0.0001). Compared with males, females 
had a greater RR for emergency department visits but a lower rate of hospitalizations and length of stay. 
Black and Other race had greater RRs than whites for emergency department visits, hospitalizations, and 
corresponding length of stay. In contrast to the reduced odds of death with greater numbers of 
cardiovascular drugs, the rate of utilization outcomes was greater as the number of cardiovascular drugs 
increased. 
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Discussion 
Our results suggest that increasing adherence to heart failure medications measured as a 10% 
increment has a favorable effect on health outcomes including reducing mortality by 9% (OR, 0.91; 95% 
CI, 0.90-0.92).  We were particularly interested in the effects of adherence on mortality because there 
were few studies available that investigated such effects in patients with heart failure from the clinical 
setting. The association of cardiovascular drug adherence on health utilization in the present study 
generally agree with our previous study of a pharmacy intervention to improve adherence but the 
intervention study had too few participants to assess an effect of adherence on mortality. Nonetheless, 
data from randomized controlled drug trials,18,19 a systematic review of interventions to improve 
adherence in patients with heart failure,10 and one international registry study20 would suggest an effect 
of treatment adherence on mortality.  In the clinical setting, two key aspects are important: 1) physician 
prescribing evidence-based medications, and 2) patients taking their medications as prescribed. For 
clinicians, the widely accepted notion that treating heart failure to a targeted dosing goal is an effective 
way of improving outcomes, including reducing mortality;21  however, prescribers may not always follow 
recommended guidelines.22-24 Notwithstanding, even when clinicians follow evidence-based guidelines, 
health outcomes will not improve for patients who do not adhere to the therapy they have been 
prescribed.   
 Adherence to medication is associated with improved health outcomes including mortality,3-7 
but our study is among the first to look at electronic medical record data from a health information 
exchange in a large, longitudinal cohort of heart failure patients from general medical settings 
(N=55,312).  We observed effects on age, sex, race, and comorbidity that we controlled for in the 
assessment of effects on health outcomes. Female patients had a slightly greater risk of death than 
males, which may be related to a less attention to cardiovascular risk factors25 and lower prescribing of 
effective medications in women than in men.26 The effects of race on mortality and utilization outcomes 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
could be the result of variation in cardiovascular medication prescribing to racial and ethnic minorities 
and their adherence to treatments.8,27  
 Class of medication has been linked to adherence rates in previous studies, specifically diuretics 
showing lower and beta-blockers showing higher adherence rates.28 In contrast, patients taking statins, 
anticoagulants, antiarrhythmics, or fixed-dose combination products tended to have better adherence 
rates.28 Consistent with these studies, we found lower adherence to diuretics compared with the other 
heart failure medications including beta-blockers.  Adverse events such as increased urinary frequency 
with subsequent limits on patient mobility are also a possible explanation for patients not adhering to 
diuretics.  Overall, our study also suggests a beneficial effect of cardiovascular medications in patients 
with heart failure from general clinical settings.  
 There are limitations to our study that are pertinent to address.  Because we used 
predominantly coded digital data from the health information exchange, we were unable to control for 
important lifestyle effects such as diet and exercise, which could have a great impact on outcomes. 
Indeed, medication adherence may also be associated with adherence to a healthy lifestyle that would 
also improve outcomes. In a randomized controlled study of candesartan, even patients who did not 
receive active therapy had improved health outcomes with higher adherence to placebo.18 Thus, 
adherence to medication therapy may be indicative of general “adherent behavior” in which patients 
also adhere to lifestyle advice.3,18 Adherence is also influenced by levels of social support, comorbid 
conditions such as depression and dementia, and patients’ perceptions of the importance of taking 
medication.5-7,29-31 Cognitive impairment is also a determinant of adherence and poor outcomes;32 
however, we did not have access to data on patient cognitive status. Our results included data for the 
period of 2004 to 2009 because our death data were valid and reconciled for this period. As such, newer 
drugs that have been shown to improve heart failure outcomes, such as sacubitril/valsartan and 
ivabradine, were not part of our adherence analysis.  These drugs are slowly becoming an integral part 
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of heart failure treatment and future studies should examine how adherence affects outcomes with 
these medications.33 It is also important to note that the PDC as a measure of adherence does not 
confirm that patients actually took their medications. Instead, the PDC only affirms medications were 
obtained from the pharmacy, suggesting that they were taken as prescribed. Finally, while the health 
information exchange allowed us to limit data that would otherwise be missing for patients visiting 
more than a single health system, we had limited data on NYHA classification, which was poorly 
documented in patients’ clinical notes.  Nonetheless, the limited data on NYHA class would not affect 
our primary results involving incremental changes in medication adherence and important health 
outcomes in patients with heart failure.   
 We conclude that incrementally increasing medication adherence reduces the risk of negative 
outcomes including death, emergency department visits, hospitalization, and length of hospital stay in 
heart failure patients. Our findings stress the importance of clinicians’ active attention to improving 
adherence and thinking of adherence as a necessary component of effective pharmacotherapy. 
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Table 1. Patient Characteristics 
Characteristic No. of Patients with  
Available Baseline Data 
Mean ± SD or Frequency (%)
Number of patients, N 55,312 – 
Mean age, years ± SD 55,312 67.7 ± 16.1 
Sex, n (%) 55,312  
Female 29,528 (54) 
Male 25,784 (46) 
Race, n (%) 46,644  
White 36,245 (65) 
Black 9766 (18) 
Other 375 (0.68) 
Hispanic 259 (0.47) 
NYHA classification, n (%) 1153  
I 253 (22) 
II 429 (37) 
III 355 (31) 
IV 116 (10) 
Comorbidites, n (%) 55,102  
Hypertension 43,156 (78) 
Diabetes 23,054 (41) 
Chronic kidney disease 11,661 (21) 
Coronary artery disease 29,788 (54) 
Myocardial infarction 10,994 (20) 
Hyperlipidemia 28,712 (52) 
Atrial fibrilation 13,978 (25) 
Stroke  5000 (9) 
Chronic obstructive pulmonary disease 17,803 (32) 
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Depression 8398 (15) 
Laboratory tests, mean ± SD  
Mean ejection fraction 10,759 50.9 ± 14 
Mean pro-BNP level 20,790 563.9 ± 851 
Mean body weight 14,252 202.9 ± 64 
Mean systolic blood pressurea  6979 133.3 ± 18 
Mean diastolic blood pressurea  6978 74.7 ± 11 
Mean hematocrit 34,778 36 ± 14 
Mean serum creatinine level 35,281 1.4 ± 1.3 
BNP = brain natriuretic peptide; NYHA = New York Heart Association; SD = standard deviation. 
aBlood pressure measurements were the mean of clinic measurements while patients were sitting. 
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Table 2. Mean PDC by Drug Class 
Drug Class N (%) Mean PDC, % ± SDa 
Overall -- 63 ± 23
ACE inhibitor 30,599 (55) 63 ± 30
Anticoagulant 14,035 (25) 59 ± 30
ARB 14,368 (26) 65 ± 29
Aspirin/Antiplatelet 14,587 (26) 60 ± 32
Beta-blocker 38,461 (70) 64 ± 28
Any calcium channel blocker 21,613 (39) 63 ± 30
Digoxin 7368 (13) 63 ± 31
Loop diuretic 31,308 (57) 56 ± 31
Potassium-sparing diuretic 3366 (6) 54 ± 33
Statin 34,273 (62) 66 ± 28
Thiazide diuretic 17,689 (32) 54 ± 32
Any diuretic 39,733 (72) 60 ± 29
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; PDC = proportion of days 
covered; SD = standard deviation. 
aA model comparing all drug classes excluding the overall has a p<0.0001. 
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Table 3. Results from Logistic Regression Model of All-Cause Mortality in Heart Failure Patients 
Category Odds Ratio 95% CI P value 
10% PDC increase 0.91 0.90-0.92 <.0001 
Gender (female vs. male) 1.06 1.00-1.11 0.0367 
Race – overalla -- -- <.0001 
Black vs. white 1.00 0.94-1.07 0.9918 
Othera vs. white 0.45 0.34-0.60 <.0001 
Age at index 1.00 0.99-1.00 <.0001 
Number of cardiovascular drugs 0.84 0.83-0.86 <.0001 
Charlson Comorbidity Index 1.25 1.23-1.26 <.0001 
CI = confidence interval; PDC = proportion of days covered. 
aOther race includes the following number of individuals who self-identified their race as Hispanic (259), 
Other (255), Asian (102), Native American (11), Multiracial (3), and American Indian/Alaskan (2). 
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Table 4. Results from Poisson Regression Models of Health Care Utilization in Heart Failure Patients 
Category Rate Ratio 95% CI P value 
Emergency Department Visits  
10% PDC increase 0.89 0.89-0.89  <.0001 
Age at index 0.99 0.99-0.99 <.0001 
Gender (female) 1.04 1.03-1.05  <.0001 
Gender (male) 1.00 1.00-1.00 - 
Race (Black) 1.28 1.27-1.29 <.0001 
Race (Othera) 1.12 1.08-1.16 <.0001 
Race (White) 1.00 1.00-1.00 - 
Number of cardiovascular drugs 1.02 1.02-1.02 <.0001 
Charlson Comorbidity Index 1.13 1.13-1.14 <.0001 
Hospital Admissions  
10% PDC increase 0.94 0.94-0.94  <.0001 
Age at index 1.00 1.00-1.00 0.0019 
Gender (female) 0.97 0.97-0.98  <.0001 
Gender (male) 1.00 1.00-1.00 - 
Race (Black) 0.77 0.76-0.78 <.0001 
Race (Othera) 0.93 0.91-0.96 <.0001 
Race (White) 1.00 1.00-1.00 - 
Number of cardiovascular drugs 1.01 1.01-1.01 <.0001 
Charlson Comorbidity Index 1.20 1.20-1.20 <.0001 
Length of Hospital Stay, days  
10% PDC increase 0.99 0.99-1.00  <.0001 
Age at index 1.00 1.00-1.00 <.0001 
Gender (female) 0.97 0.96-0.97  <.0001 
Gender (male) 1.00 1.00-1.00 - 
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Category Rate Ratio 95% CI P value 
Race (Black) 1.10 1.10-1.10 <.0001 
Race (Othera) 1.05 1.03-1.06 <.0001 
Race (White) 1.00 1.00-1.00 - 
Number of cardiovascular drugs 1.02 1.02-1.02 <.0001 
Charlson Comorbidity Index 1.15 1.15-1.15 <.0001 
CI = confidence interval; PDC = proportion of days covered. 
aOther race includes the following number of individuals who self-identified their race as Hispanic (259), 
Other (255), Asian (102), Native American (11), Multiracial (3), and American Indian/Alaskan (2). 
 
 
